Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

The company is finding ways to overcome the headwinds it will encounter in the medium term.

Merck’s MRK stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained bullish momentum. The 50-day moving average is a short-term ...

We recently published 7 Best ASX Stocks to Buy Right Now. Immutep Limited (NASDAQ:IMMP) is one of the best ASX stocks.

They could grow into their valuation over the next few years.

Zydus will commercialise FYB206 in North America, while Formycon will lead development, regulatory filings and supply, with a ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, ...

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS ...

The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly ...